PDF(Pubmed)
Abstract：
This is the first report of the health economic benefits derived from preventing infections through Immunoglobulin Replacement Therapy (IgRT) in patients with secondary immunodeficiency due to hematological malignancies. We conducted a retrospective population-based cohort study using patient medical history and pharmacy data from the Hospital Clínico San Carlos for 21 patients between 2011 and 2020. The pharmacoeconomic impact of using prophylactic IgRT was assessed by comparing characteristics of the SID patients 1 year before and after initiating IgRT measured by direct medical and tangible indirect costs. Results indicate a marked reduction in hospitalization days following IgRT initiation, decreasing from an average of 13.9 to 6.1 days per patient, with the elimination of ICU admissions. While emergency department visits decreased significantly, the number of routine consultations remained unchanged. Notably, absenteeism from work dropped substantially. The financial analysis revealed significant reductions in medication use and fewer ancillary tests, resulting in considerable cost savings. Specifically, total expenditure dropped from €405,088.18 pre-IgRT to €295,804.42 post-IgRT-including the cost of IgRT itself at €156,309.60. Overall, the annual savings amounted to €109,283.84, validating the cost-effectiveness of IgRT in managing SID in patients with hematological cancers.
摘要：
这是关于通过免疫球蛋白替代疗法（IgRT）预防血液恶性肿瘤引起的继发性免疫缺陷患者感染的健康经济效益的第一份报告。我们进行了一项基于人群的回顾性队列研究，使用2011年至2020年期间21例患者的患者病史和药房数据。使用预防性IgRT的药物经济学影响是通过比较SID患者在开始IgRT之前和之后1年的特征来评估的，该特征是通过直接医疗和有形间接成本来测量的。结果表明，IgRT开始后住院天数明显减少，从每名患者的平均13.9天减少到6.1天，随着ICU入院的取消。虽然急诊科就诊人数显著减少，例行磋商的次数保持不变。值得注意的是,旷工率大幅下降。财务分析显示，药物使用显着减少，辅助检查减少，从而节省了大量的成本。具体来说,总支出从IgRT前的405,088.18欧元下降到IgRT后的295,804.42欧元-包括IgRT本身的成本为156,309.60欧元。总的来说,每年节省的费用为109,283.84欧元,验证了IgRT在治疗血液肿瘤患者的SID方面的成本效益.
